Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Overview of Myeloid Cell Line
3.2. Origin, Differentiation and Identification of Myeloid Cells
3.3. Multifaceted Functions of Myeloid Cells
3.4. Receptors Controlling Migration and Activation of Myeloid Cells
3.5. Recruitment of Myeloid Cells in Tumor Microenvironment (TME)
3.6. Role of Myeloid Cells in Tumor Progression and Suppression
3.7. Approaches to Select and Target Myeloid Cells in TME
3.8. Myeloid Cells and Anti-tumor Therapies
3.9. Factors Affecting Therapeutic Efficacy of Myeloid Cell Targeting Therapeutics
3.10. Challenges Associated with Myeloid Cell Targeting
3.11. Future Perspectives

4. MYELOID CELLS TARGETING THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Myeloid Cells Targeting Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Indication(s)
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Biological Target(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Combination Drug(s)
4.2.9. Analysis by Line of Treatment
4.2.10. Analysis by Dosing Frequency
4.3. Myeloid Cells Targeting Therapeutics Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
4.3.5. Most Active Players: Analysis by Phase of Development of Drugs

5. MYELOID CELLS TARGETING THERAPEUTICS DEVELOPERS: COMPANY PROFILES
5.1. Companies with Drugs in Advanced Stages of Development
5.1.1. ChemoCentryx
5.1.1.1. Company Overview
5.1.1.2. Financial Information
5.1.1.3. Drug Portfolio
5.1.1.4. Recent Developments and Future Outlook
5.1.2. Daiichi Sankyo
5.1.2.1. Company Overview
5.1.2.2. Financial Information
5.1.2.3. Drug Portfolio
5.1.2.4. Recent Developments and Future Outlook
5.1.3. Gilead Sciences
5.1.3.1. Company Overview
5.1.3.2. Financial Information
5.1.3.3. Drug Portfolio
5.1.3.4. Recent Developments and Future Outlook
5.2. Companies with Multiple Therapeutic Development Programs
5.2.1. Janssen Biotech
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Drug Portfolio
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Roche
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Drug Portfolio
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Pfizer
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Drug Portfolio
5.2.3.4. Recent Developments and Future Outlook
5.2.4. GlaxoSmithKline
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Drug Portfolio
5.2.4.4. Recent Developments and Future Outlook
5.2.5. Macrophage Pharma
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Drug Portfolio
5.2.5.4. Recent Developments and Future Outlook
5.2.6. Enlivex
5.2.6.1. Company Overview
5.2.6.2. Financial Information
5.2.6.3. Drug Portfolio
5.2.6.4. Recent Developments and Future Outlook
5.2.7. Immune-Onc Therapeutics
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Drug Portfolio
5.2.7.4. Recent Developments and Future Outlook
5.2.8. Infinity Pharmaceuticals
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Drug Portfolio
5.2.8.4. Recent Developments and Future Outlook
5.2.9. AstraZeneca
5.2.9.1. Company Overview
5.2.9.2. Financial Information
5.2.9.3. Drug Portfolio
5.2.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIALS ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Myeloid Cells Targeting Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Type of Sponsor / Collaborator
6.2.4. Analysis by Registration Year and Type of Study
6.2.5. Analysis by Study Design
6.2.6. Analysis by Patient Enrollment
6.2.7. Year-wise Trend of Completed and Recruiting Trials
6.2.8. Analysis by Age Category
6.2.9. Analysis by Phase of Development and Trial Status
6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.2.12. Analysis by Trial Location
6.2.13. Analysis by Trial Status and Geography

7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Myeloid Cells Targeting Therapeutics: List of Publications
7.3. Analysis by Year of Publication
7.4. Analysis by Emerging Focus Area
7.5. Analysis by Type of Publication
7.6. Analysis by Therapeutic Area
7.7. Analysis by Target Indication
7.8. Top Journals: Analysis by Number of Publications
7.9. Top Authors: Analysis by Number of Publications

8. ACADEMIC GRANTS ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Myeloid Cells Targeting Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded
8.5. Analysis by Type of Funding Institute Center
8.6. Popular NIH Departments: Analysis by Number of Grants
8.7. Analysis by Support Period
8.8. Analysis by Emerging Focus Area
8.9. Analysis by Purpose of Grants
8.10. Analysis by Grant Activity Code
8.11. Analysis by Local Recipients
8.12. Analysis by Type of Recipient Organization
8.13. Popular Recipient Organization: Analysis by Number of Grants
8.14. Popular Recipient Organization: Analysis by Amount Awarded
8.15. Prominent Program Officers: Analysis by Number of Grants
8.16. Analysis by Study Section
8.17. Analysis by Type of Grant Application
8.18. Analysis by Funding Institute Center and Support Year

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Analysis Methodology and Key Parameters
9.2. Partnership Models
9.3. Myeloid Cells Targeting Therapeutics: List of Partnerships and Collaborations
9.4. Analysis by Year of Partnership
9.5. Analysis by Type of Partnership
9.6. Analysis by Year and Type of Partnership
9.7. Analysis by Type of Myeloid Cells Targeted
9.8. Analysis by Type of Molecule
9.9. Analysis by Therapeutic Area
9.10. Analysis by Type of Partner
9.11. Most Active Players: Analysis by Number of Partnerships
9.12. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Type of Funding
10.3. Myeloid Cells Targeting Therapeutics: List of Funding Instances
10.4. Analysis by Year of Funding
10.5. Analysis by Amount Invested
10.6. Analysis by Type of Funding
10.7. Analysis by Type of Funding and Amount Invested
10.8. Analysis by Year, Type of Funding and Amount Invested
10.9. Analysis by Type of Myeloid Cells Targeted
10.10. Analysis by Therapeutic Area
10.11. Analysis by Target Indication
10.12. Most Active Players: Analysis by Number of Funding Instances
10.13. Most Active Players: Analysis by Amount Invested
10.14. Key Investors: Analysis by Number of Funding Instances
10.15. Analysis by Geographical Regions
10.16. Analysis by Year and Type of Funding
10.17. Summary of Funding Instances
11. START-UP HEALTH INDEXING
11.1. Analysis Methodology and Key Parameters
11.2. Analysis by Pipeline Strength
11.3. Analysis by Pipeline Maturity
11.4. Analysis by Indication Diversity
11.5. Analysis by Financial Support
11.6. Analysis by Number of Investors
11.7. Analysis by Partnership Activity
11.8. Start-up Health Indexing: Roots Analysis Perspective
12. CASE STUDY: MACROPHAGE-BASED THERAPEUTICS DEVELOPERS
12.1 Overview and Key Parameters
12.2. Macrophage-based Therapeutics: List of Therapies
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Type of Molecule
12.2.3. Analysis by Target Indication(s)
12.2.4. Analysis by Therapeutic Area
12.3. Macrophage -based Therapeutic Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Forecast Methodology and Key Assumptions
13.1. Global Myeloid Cells Targeting Therapeutics Market, 2021-2035
13.2. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Type of Molecule
13.2.1. Myeloid Cells Targeting Therapeutics Market for Small Molecules, 2021-2030
13.2.2. Myeloid Cells Targeting Therapeutics Market for Biologics, 2021-2030
13.3. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Therapeutic Area
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.1. Myeloid Cells Targeting Therapeutics Market for Oncological Disorders, 2021-2030
13.3.2. Myeloid Cells Targeting Therapeutics Market for Rare Disorders, 2021-2030
13.4. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Route of Administration
13.4.1. Myeloid Cells Targeting Therapeutics Market for Intravenous Route, 2021-2030
13.4.2. Myeloid Cells Targeting Therapeutics Market for Oral Route, 2021-2030
13.5. Global Myeloid Cells Targeting Therapeutics Market, 2021-2030: Distribution by Geography
13.5.1. Myeloid Cells Targeting Therapeutics in North America, 2021-2030
13.5.2. Myeloid Cells Targeting Therapeutics in Europe, 2021-2030
13.5.3. Myeloid Cells Targeting Therapeutics in Asia Pacific, 2021-2030

14. EXECUTIVE INSIGHTS
14.1. Montis Bioscience
14.1.1. Company Snapshot
14.1.2. Interview Transcript: Rene Hoet (Chief Scientific Officer)
14.2. Carisma Therapeutics
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Tom Wilton (Chief Business Officer)

15. APPENDIX 1: LIST OF FIGURES AND TABLES

16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS